好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Herpes labialis, Chlamydophila pneumoniae, Helicobacter pylori and cytomegalovirus infections and risk of dementia: The Framingham Heart Study
Aging, Dementia, and Behavioral Neurology
Aging and Dementia Posters (7:00 AM-5:00 PM)
033
Investigate whether exposure to Herpes simplex  (manifested as herpes labialis), Chlamidophyla pneumoniae (C Pneumoniae), Helicobacter pylori (H pylori) and cytomegalovirus (CMV) modifies the risk of  dementia in a populational cohort.
An association between chronic infectious diseases and development of dementia has been suspected for decades, based on the finding of pathogens in post-mortem brain tissue and on serological evidence. However, important questions remain regarding possible confounders, reverse causality, whether those organisms cause dementia or are “innocent bystanders”, and how accurate, reproducible and generalizable those findings are.
Questionnaires regarding incidence of herpes infections were applied to  Original Framingham Heart Study cohort participants. Serologies for C pneumoniae, H pylori and CMV were obtained in  Original and Offspring cohort participants. Participants are under continuous surveillance for dementia; brain MRI and neuropsychological batteries were administered to Offspring participants from 1999 to 2005. The association between each infection and incident dementia was tested with Cox  models. Linear regression  models were used to investigate associations between MRI or neuropsychological parameters and serologies
Herpes labialis was associated with reduced 10-year  dementia risk (HR 0.66, CI 0.46-0.97). H pylori antibodies were associated with worse global cognition (β -0.14 , CI -0.22, -0.05). There was no association between positive C pneumonia, H Pylori, CMV serologies and dementia incidence, total brain volume, and white matter hyperintensities.
Herpes labialis may be associated with reduced 10-year dementia risk. This unexpected result requires confirmation, particularly regarding how accurately clinical episodes are captured, and further characterization, especially concerning treatment effects.
Authors/Disclosures
Eduardo M. Zilli, MD (UT Health, San Antonio)
PRESENTER 		Dr. Zilli has nothing to disclose.
Adrienne O'Donnell No disclosure on file
Joel Salinas, MD, MBA, MSc, FAAN Dr. Salinas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai, Inc. Dr. Salinas has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lilly, Inc. Dr. Salinas has stock in Isaac Health.
Hugo Javier Aparicio, MD, MPH (Boston University) Dr. Aparicio has received research support from 好色先生. Dr. Aparicio has received research support from Alzheimer's Association. Dr. Aparicio has received research support from National Institutes of Health. Dr. Aparicio has received personal compensation in the range of $10,000-$49,999 for serving as a expert panelist for the Memory & Healthy Aging Program with Cedars-Sinai.
No disclosure on file
No disclosure on file
Alexa Beiser Alexa Beiser has nothing to disclose.
Sudha Seshadri, MD, FAAN (Glenn Biggs Institute for Alzheimer'S and Neurodegenerative Diseases) Dr. Seshadri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. The institution of Dr. Seshadri has received research support from NIH. The institution of Dr. Seshadri has received research support from Alzheimer Association.